For a general timeline of the Bayh-Dole Act, see this page. 1999. September 3. Ralph Nader, James Love, and Robert Weissman requests the NIH Director Harold Varmus, M.D., to use royalty-free rights and give the WHO access to several U.S. government… Continue Reading
For a general timeline of the Bayh-Dole Act, see this page. 1980. December 12. The Bayh-Dole Act was enacted into law as part of Public Law 96-517, including Section 203 that provide march-in rights. 1984. November 8. The Bayh-Dole statute was… Continue Reading
(UPDATE: The NIH provided a response to our comments on March 11, 2019) On February 22, 2019, Knowledge Ecology International (KEI), Public Citizen, Social Security Works (SSW) and the Union for Affordable Cancer Treatment (UACT) jointly submitted comments to the… Continue Reading
(UPDATE: The NIH provided a response to our comments on April 22, 2019) On February 20, 2019, KEI submitted comments to the Federal Register notice 84 FR 1764 on the “Prospective Grant of an Exclusive Patent License: Use of the… Continue Reading
The WHO Essential Medicines List is a major WHO tool used to expand access to medicines. In 2017, the WHO issued the 20th Essential Medicines List (EML) which was the 40th anniversary of the list. The WHO is currently in… Continue Reading
On Thursday February 7, 2019, KEI submitted comments and intent to testify at the hearing for the 2019 US Trade Representative’s Special 301 review process. This year’s hearing will take place on Wednesday February 27, 2019 at the Office of… Continue Reading
On August 27, 2018, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) filed comments to the NIH regarding the prospective grant of two separate exclusive licenses to Sinotau Pharmaceutical Group and Molecular Targeting Technologies, Inc. (MTTI),… Continue Reading
In a resolution dated the 9th of March, 2018, Minister Carmen Castillo Taucher of Chile’s Ministry of Health has announced that there are sufficient public health reasons to support a compulsory license on medicines for the hepatitis C virus (HCV),… Continue Reading
On March 8, 2018, USTR and the interagency committee on the Special 301 held a hearing. KEI was one of the groups testifying. More on this process here: https://keionline.org/ustr/special301 I began our oral testimony discussing President Trump’s promise, during the… Continue Reading
Bayh-Dole cases involving royalty free or march-in rights 1997 Cellpro case This was a strong case involving two competing medical devices, both invented on NIH grants, and a bad ending. The NIH rejection of the Cellpro march-in request led to… Continue Reading